AlphaVax says trial immunization begins

In the first study, healthy volunteers are being immunized with a human version of an alphavaccine that was shown to be effective in protecting against congenital cytomegalovirus disease in a preclinical study. Results from this trial will be used to design future studies in target populations such as solid organ transplant recipients.

In the second study, volunteers are being immunized with an influenza alphavaccine that contains the hemagglutinin gene from a single strain of influenza and was shown to be effective in protecting animals against experimental influenza infection. Subsequent trials will test additional vaccine candidates for seasonal and potentially pandemic strains of influenza.

These projects were funded in part by grants from the National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services.